Currently, the NK-92/5.28.z cell line is being tested in a phase I clinical trial for the treatment of recurrent ERBB2-positive glioblastoma [21], and the results could aid in extending this approach to other disease entities. The gene discussed is ERBB2; the disease is glioblastoma.